VTRS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.02
Percentage change -0.23	%

Peers: PFE MRK BMY JNJ ABBV GSK LLY AMGN SNY NVS

| Held by: VTI VOO RSP VB SPY IVV VO VBR CALF XLV

Scroll to Statements

Index	S&P 500	P/E	-	EPS (ttm)	-3.18	Insider Own	2.55%	Shs Outstand	1.19B	Perf Week	-0.78%
Market Cap	10.39B	Forward P/E	3.64	EPS next Y	2.43	Insider Trans	0.20%	Shs Float	1.14B	Perf Month	4.36%
Enterprise Value	24.00B	PEG	-	EPS next Q	0.55	Inst Own	81.89%	Short Float	4.32%	Perf Quarter	-3.28%
Income	-3790.10M	P/S	0.73	EPS this Y	-16.13%	Inst Trans	-2.63%	Short Ratio	3.14	Perf Half Y	-29.71%
Sales	14.26B	P/B	0.67	EPS next Y	9.30%	ROA	-8.83%	Short Interest	49.41M	Perf YTD	-28.92%
Book/sh	13.20	P/C	12.21	EPS next 5Y	0.59%	ROE	-21.25%	52W High	13.55 -34.69%	Perf Year	-11.94%
Cash/sh	0.72	P/FCF	5.45	EPS past 3/5Y	20.30% -	ROIC	-12.63%	52W Low	6.85 29.20%	Perf 3Y	-17.29%
Dividend Est.	0.48 (5.41%)	EV/EBITDA	6.51	Sales past 3/5Y	-6.26% 5.04%	Gross Margin	38.88%	Volatility	1.58% 1.82%	Perf 5Y	-45.13%
Dividend TTM	0.48 (5.42%)	EV/Sales	1.68	EPS Y/Y TTM	-6809.78%	Oper. Margin	5.76%	ATR (14)	0.26	Perf 10Y	-87.97%
Dividend Ex-Date	May 23, 2025	Quick Ratio	0.86	Sales Y/Y TTM	-6.88%	Profit Margin	-26.57%	RSI (14)	52.83	Recom	2.73
Dividend Gr. 3/5Y	13.30% -	Current Ratio	1.58	EPS Q/Q	-2808.28%	SMA20	0.95%	Beta	0.89	Target Price	10.83
Payout	-	Debt/Eq	0.92	Sales Q/Q	-11.28%	SMA50	4.48%	Rel Volume	0.54	Prev Close	8.87
Employees	32000	LT Debt/Eq	0.92	Earnings	May 08 BMO	SMA200	-16.33%	Avg Volume	15.72M	Price	8.85
IPO	Mar 17, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.65% 0.59%	Trades		Volume	8,441,727	Change	-0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	Goldman	Neutral	$10
Jul-19-24	Resumed	Jefferies	Buy	$15
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24
Mar-08-21	Downgrade	Goldman	Buy → Neutral	$20 → $15
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral	$21 → $18
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$17
Jan-05-21	Initiated	Argus	Hold

Show Previous Ratings

Jun-17-25 12:03AM	3 Reasons to Avoid VTRS and 1 Stock to Buy Instead (StockStory)
Jun-12-25 04:30PM	Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 (PR Newswire)
Jun-10-25 05:00AM	Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris (Zacks)
Jun-09-25 09:29AM	3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats (Zacks)
07:22AM	VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review (StockStory)
02:04PM	Loading…
Jun-06-25 02:04PM	Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout (Insider Monkey)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
Jun-02-25 08:00AM	Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (PR Newswire)
May-27-25 06:59AM	Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada (PR Newswire)
May-23-25 05:45AM	Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS (PR Newswire)
May-22-25 06:59AM	Viatris to Participate in Upcoming Investor Conferences (PR Newswire)
May-09-25 12:39PM	Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks)
03:21AM	Viatris Inc (VTRS) Q1 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on ... (GuruFocus.com)
02:33AM	Q1 2025 Viatris Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-25 03:49PM	Analyst Report: Viatris Inc. (Morningstar Research) +5.70%
12:38PM	Loading…
12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks)
09:30AM	Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates (Zacks)
08:03AM	Viatris new form of old pain drug scores in large trials (BioPharma Dive)
07:10AM	Viatris: Q1 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook (PR Newswire)
06:45AM	Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO Low Dose Patch for Birth Control in Women of Childbearing Potential (PR Newswire)
06:30AM	Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain (PR Newswire)
May-07-25 12:27PM	Viatris Q1 Earnings Preview: Analysts expect profit to decline by about 27% (Seeking Alpha)
08:15AM	Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:59AM	Viatris Announces Quarterly Dividend (PR Newswire)
May-05-25 04:30PM	Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors (PR Newswire)
09:15AM	Unveiling Viatris (VTRS) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
12:40AM	2 S&P 500 Stocks Worth Investigating and 1 to Avoid (StockStory)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
10:00AM	Loading…
10:00AM	Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 07:42PM	Viatris Inc. (VTRS): Among the Worst Performing Stocks in S&P 500 So Far in 2025 (Insider Monkey)
Apr-29-25 09:56AM	Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now (Insider Monkey)
Apr-28-25 05:05AM	Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest (StockStory)
Apr-27-25 03:06PM	Viatris Inc. (VTRS): Among Billionaire Ken Fisher's Healthcare Stock Picks with Massive Upside Potential (Insider Monkey)
08:20AM	VTRS SHAREHOLDER REVIEW: Viatris Inc. (NASDAQ:VTRS) was Sued for Fraud after 15% Stock Drop Investors are Urged to Contact BFA Law (GlobeNewswire)
Apr-25-25 09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
06:59AM	Viatris to Present at the BofA Securities 2025 Healthcare Conference (PR Newswire)
Apr-24-25 05:01AM	3 Reasons VTRS is Risky and 1 Stock to Buy Instead (StockStory)
Apr-23-25 12:22PM	Is Viatris Inc. (NASDAQ:VTRS) the Best Cheap Stock to Buy Under $10? (Insider Monkey)
Apr-22-25 07:17AM	Viatris files applications in Japan for approval of Effexor to treat GAD (Pharmaceutical Business Review)
Apr-21-25 06:59AM	Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR for the Treatment of Generalized Anxiety Disorder (PR Newswire)
Apr-14-25 09:06AM	Is Viatris Inc. (VTRS) The Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
06:59AM	Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer (PR Newswire)
Apr-11-25 09:55AM	Viatris Inc. (VTRS): Among the High-Dividend Stocks to Invest In Under $10 (Insider Monkey)
Apr-09-25 04:22AM	3 Beaten-Down Stocks That Are Trading Below Their Book Values (Motley Fool) +5.84%
Apr-08-25 09:56AM	Viatris to Pay $335 Million for Settlement of Opioid-Related Claims (Zacks)
Apr-07-25 09:27AM	Viatris to Pay Up to $335 Million in Opioid Settlement (GuruFocus.com)
06:59AM	Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims (PR Newswire)
Apr-03-25 02:19PM	Analyst Report: Viatris Inc. (Morningstar Research) -5.77%
Apr-01-25 01:04PM	Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility Hagens Berman (GlobeNewswire)
Mar-30-25 07:05PM	Viatris Inc. (VTRS): Among the Oversold Stocks to Buy in 2025 Amid Inflation Fears (Insider Monkey)
08:20AM	John Hancock Corporate Bond ETF Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 06:59AM	Viatris to Report First Quarter 2025 Financial Results on May 8, 2025 (PR Newswire)
Mar-25-25 02:48PM	Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility Hagens Berman (GlobeNewswire)
02:12PM	Is Viatris Inc. (NASDAQ:VTRS) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-21-25 01:32PM	Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility Hagens Berman (GlobeNewswire)
Mar-18-25 03:25PM	Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility - Hagens Berman (Newsfile)
05:01AM	Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment (StockStory)
Mar-17-25 03:26PM	Is Viatris Inc. (VTRS) the Best Nasdaq Stock Under $20 to Buy Now? (Insider Monkey)
Mar-13-25 05:01AM	Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Mar-11-25 09:01AM	1 Healthcare Stock to Target This Week and 2 to Turn Down (StockStory)
Mar-09-25 08:32PM	Why Viatris Inc. (VTRS) Is Plunging So Far In 2025 (Insider Monkey)
Mar-05-25 04:30PM	Viatris to Present at the Barclays 27th Annual Global Healthcare Conference (PR Newswire)
04:03AM	Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers (StockStory)
Mar-01-25 02:54PM	Is Viatris Inc. (VTRS) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-28-25 07:30PM	Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings (Zacks)
09:40AM	Why Viatris Inc. (VTRS) Went Down on Thursday (Insider Monkey)
02:28AM	Q4 2024 Viatris Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Viatris Inc (VTRS) Q4 2024 Earnings Call Highlights: Strong Cash Flow and Debt Reduction Amid ... (GuruFocus.com)
Feb-27-25 04:33PM	Analyst Report: Viatris Inc. (Morningstar Research) -15.21%
04:33PM	S&P 500 Gains and Losses Today: Nvidia Leads Chip, AI Stocks Lower (Investopedia)
03:06PM	Why Viatris (VTRS) Shares Are Falling Today (StockStory)
01:27PM	eBay, Rolls-Royce, Viatris: Market Minute (Yahoo Finance Video)
11:02AM	Viatris plummets sharply on disappointing fourth-quarter, 2025 outlook (Investing.com)
08:52AM	Is Viatris Inc. (VTRS) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
08:35AM	Viatris Shares Decline After Earnings Miss, Lower 2025 Guidance (GuruFocus.com)
07:55AM	Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates (Zacks)
07:11AM	Viatris (NASDAQ:VTRS) Misses Q4 Revenue Estimates, Stock Drops (StockStory)
07:02AM	Viatris: Q4 Earnings Snapshot (Associated Press Finance)
06:45AM	Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance (PR Newswire)
06:30AM	Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend (PR Newswire)
Feb-26-25 12:13PM	Viatris Inc. (NASDAQ:VTRS): A Bull Case Theory (Insider Monkey)
12:03PM	Idorsias Tryvio deal collapses, forcing company to find cash urgently (Pharmaceutical Technology)
08:12AM	Viatris Earnings: What To Look For From VTRS (StockStory)
Feb-24-25 09:16AM	Stay Ahead of the Game With Viatris (VTRS) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Feb-21-25 04:07AM	Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Feb-20-25 10:00AM	Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline (Zacks)
Feb-19-25 10:45AM	Uniting Against AMR: Global Solutions Need Local and Global Collaboration (ACCESSWIRE)
04:01AM	Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest (StockStory)
Feb-18-25 04:35AM	3 Reasons to Sell VTRS and 1 Stock to Buy Instead (StockStory)
Feb-17-25 04:45PM	50 Years of Service: From Milkman's Son to Advancing Access to Medicines (ACCESS Newswire)
Feb-14-25 04:01AM	Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Feb-13-25 04:01AM	ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group (StockStory)
Feb-03-25 04:30PM	Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (PR Newswire)
Jan-22-25 07:02PM	Analyst Report: Viatris Inc. (Morningstar Research)
Jan-20-25 09:10PM	Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? (Insider Monkey)
Jan-16-25 12:06AM	Is Viatris Inc. (VTRS) Among Wednesday's Losers? (Insider Monkey)
Jan-15-25 05:02PM	S&P 500 Gains and Losses Today: Bank Earnings, Soft Inflation Help Boost Index (Investopedia)

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Scott Andrew	Chief Executive Officer	May 12 '25	Buy	8.94	60,000	536,262	292,807	May 14 06:00 PM
Le Goff Corinne	Chief Commercial Officer	Apr 15 '25	Option Exercise	0.00	41,112	0	60,441	Apr 16 06:00 PM
FINNEY ELISHA W	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	37,832	Mar 05 07:00 PM
Le Goff Corinne	Chief Commercial Officer	Mar 04 '25	Option Exercise	0.00	37,894	0	36,721	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 04 '25	Option Exercise	0.00	207,325	0	328,250	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 03 '25	Option Exercise	0.00	19,348	0	144,590	Mar 05 07:00 PM
Vivaldi Coelho Rogerio	Director	Mar 04 '25	Option Exercise	0.00	21,691	0	21,691	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 04 '25	Option Exercise	0.00	96,431	0	266,825	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '25	Option Exercise	0.00	146,700	0	221,178	Mar 05 07:00 PM
PARRISH MARK W	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	140,395	Mar 05 07:00 PM
Lyons Dillon JoEllen	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	77,691	Mar 05 07:00 PM
KORMAN HARRY	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	113,937	Mar 05 07:00 PM
Groothuis Leo Frans	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	40,350	Mar 05 07:00 PM
HIGGINS MELINA E	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	121,213	Mar 05 07:00 PM
Malik Rajiv	Director	Mar 04 '25	Option Exercise	0.00	892,603	0	1,407,415	Mar 05 07:00 PM
Malik Rajiv	Director	Mar 03 '25	Option Exercise	0.00	89,430	0	587,599	Mar 05 07:00 PM
CORNWELL W DON	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	80,342	Mar 05 07:00 PM
KILTS JAMES M	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	136,422	Mar 05 07:00 PM
MARK RICHARD A	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	91,310	Mar 05 07:00 PM
Roman Brian	Chief Legal Officer	Mar 04 '25	Option Exercise	0.00	206,263	0	265,061	Mar 05 07:00 PM
Roman Brian	Chief Legal Officer	Mar 03 '25	Option Exercise	0.00	18,345	0	84,494	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Mar 04 '25	Option Exercise	0.00	32,472	0	41,815	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Jan 01 '25	Option Exercise	0.00	24,065	0	23,084	Jan 03 06:00 PM
Campbell Paul	See Remarks	Nov 11 '24	Sale	12.88	26,925	346,686	126,901	Nov 12 07:00 PM
Campbell Paul	Officer	Nov 11 '24	Proposed Sale	12.88	26,925	346,686		Nov 12 04:30 PM
Malik Rajiv	Director	Sep 12 '24	Sale	11.66	139,681	1,628,164	505,838	Sep 13 06:00 PM
Malik Rajiv	Director	Sep 12 '24	Sale	11.71	60,319	706,553	0	Sep 13 06:00 PM
Malik Rajiv	Director	Aug 30 '24	Sale	12.00	50,000	600,000	60,319	Aug 30 06:16 PM
Malik Rajiv	Director	Aug 28 '24	Sale	11.90	50,000	595,075	110,319	Aug 30 06:16 PM
Malik Rajiv	Director	Aug 21 '24	Sale	11.75	100,000	1,175,260	360,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 23 '24	Sale	11.75	100,000	1,175,100	160,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 22 '24	Sale	11.73	100,000	1,172,630	260,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 20 '24	Proposed Sale	11.80	600,000	7,080,000		Aug 20 12:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Viatris Inc

Upgrade your FINVIZ experience